UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

PloS one, 2011-09, Vol.6 (9), p.e22871-e22871

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

PloS one, 2012-05, Vol.7 (5), p.e36673-e36673

2012

Link zum Volltext

Verfügbarkeit prüfen

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study

PloS one, 2017-12, Vol.12 (12), p.e0187517-e0187517

2017

Link zum Volltext

Verfügbarkeit prüfen

Choice of effect measure in HIV randomized trials

AIDS (London), 2015-09, Vol.29 (15), p.2057-2060

Flandre, Philippe

2015

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test

Life (Basel, Switzerland), 2022-12, Vol.12 (12), p.2064

2022

Link zum Volltext

Verfügbarkeit prüfen

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

PloS one, 2011-09, Vol.6 (9), p.e24798

2011

Link zum Volltext

Verfügbarkeit prüfen

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

PloS one, 2012-07, Vol.7 (7), p.e41390-e41390

2012

Link zum Volltext

Verfügbarkeit prüfen

Some current issues in the design of HIV noninferiority trials

AIDS (London), 2014-08, Vol.28 (13), p.1921-1929

FLANDRE, Philippe

2014

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

PloS one, 2015-06, Vol.10 (6), p.e0127816-e0127816

2015

Link zum Volltext

Verfügbarkeit prüfen

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set

PloS one, 2013-03, Vol.8 (3), p.e59014

2013

Link zum Volltext

Verfügbarkeit prüfen

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

PloS one, 2013-10, Vol.8 (10), p.e74078-e74078

2013

Link zum Volltext

Verfügbarkeit prüfen

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

PloS one, 2013-01, Vol.8 (1), p.e54381-e54381

2013

Link zum Volltext

Verfügbarkeit prüfen

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

Current HIV research, 2011-01, Vol.9 (1), p.31

2011

Link zum Volltext

Verfügbarkeit prüfen

The Short-Term and Long-Term Hazard Ratio Model: Parameterization Inconsistency

The American statistician, 2021-10, Vol.75 (4), p.376-382

2021

Link zum Volltext

Verfügbarkeit prüfen

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Journal of acquired immune deficiency syndromes (1999), 2019-05, Vol.81 (1), p.44

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136

AIDS (London), 2010-09, Vol.24 (15), p.2365-2374

2010

Link zum Volltext

Verfügbarkeit prüfen

Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir

Journal of acquired immune deficiency syndromes (1999), 2017-08, Vol.75 (4), p.448

2017

Link zum Volltext

Verfügbarkeit prüfen

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002―2011 survey

AIDS (London), 2012-05, Vol.26 (8), p.971-975

2012

Link zum Volltext

Verfügbarkeit prüfen

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

AIDS (London), 2008-01, Vol.22 (3), p.385-393

2008

Link zum Volltext

Verfügbarkeit prüfen

Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?

AIDS (London), 2016-06, Vol.30 (9), p.1433-1438

2016

Link zum Volltext

Verfügbarkeit prüfen

Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study

Journal of acquired immune deficiency syndromes (1999), 2012-12, Vol.61 (5), p.557

2012

Link zum Volltext

Verfügbarkeit prüfen

Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml

AIDS (London), 2011-01, Vol.25 (3), p.341-344

2011

Link zum Volltext

Verfügbarkeit prüfen

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

AIDS (London), 2002-12, Vol.16 (18), p.2447-2454

2002

Link zum Volltext

Verfügbarkeit prüfen

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach

Medicine (Baltimore), 2015-09, Vol.94 (39), p.e1668-e1668

2015

Link zum Volltext

Verfügbarkeit prüfen

Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1

Journal of medical virology, 2013-01, Vol.85 (1), p.8-15

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study

Choice of effect measure in HIV randomized trials

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

Some current issues in the design of HIV noninferiority trials

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

The Short-Term and Long-Term Hazard Ratio Model: Parameterization Inconsistency

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136

Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002―2011 survey

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?

Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study

Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach

Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1

Aktive Filter

Suchergebnisse filtern